FDA hits Lundbeck with untitled letter over efficacy claims on migraine drug Vyepti

Lundbeck’s online promotion of migraine med Vyepti has caught the attention of the FDA, with the agency inking an untitled letter that calls out the company for potentially misleading efficacy clai | The FDA took issue with multiple claims describing Vyepti's efficacy listed on Lundbeck's healthcare provider webpage for the drug.